EISAI CO
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 561
- Registration Number
- NCT02300532
Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 507
- Registration Number
- NCT02300506
A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02289599
Phase 1 Study of E7090 in Subjects With Solid Tumor
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02275910
- Locations
- 🇯🇵
Eisai Trial Site #1, Osaka, Japan
🇯🇵Eisai Trial Site #3, Osaka, Japan
🇯🇵Eisai Trial Site #2, Osaka, Japan
Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT02269995
Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02268838
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT02227693
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 530
- Registration Number
- NCT02225470
- Locations
- 🇨🇳
33 Eisai Trial Site, Beijing, Beijing, China
🇨🇳10 Eisai Trial Site, Nanning, Guangxi, China
🇨🇳20 Eisai Trial Site, Guangzhou, Guangdong, China
A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly Males
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT02225288
A Study of E6011 in Japanese Subjects With Rheumatoid Arthritis
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT02196558
© Copyright 2024. All Rights Reserved by MedPath